Source: International Congress 2014 – COPD: points to ponder
Disease area: Airway diseases

Abstract

Aim: to determine the role of initial and dynamic levels of different inflammatory markers as indicators of COPD treatment.Methods: 50 patients with verified stable COPD, divided into 2 groups (gr): gr1 – 23 patients with COPD GOLD II (age – 60,4±0,94 years, men – 21 (96,8%), women – 2 (8,3%)), gr 2 – 27 patients with COPD GOLD III-IV (age – 66,5±0,71 years, men – 24 (88,8%), women – 3 (11,2%)). General analysis, plasma levels of C-reactive protein (C-RP), fibrinogen, matrix metalloproteinase (MMP) -2 and 9, hyaluronic acid on visit 1 (before correction of basic treatment), on visit 2 – after 12 month of regular basic treatment, statistic analysis. Control group was 26 healthy people (age – 58,9±11,5, men – 18 (69,3%), women – 8 (30,7%)).Results: are present in table 1.

Initial and dynamic levels of inflammatory markers in patients with COPD

Parameter	Visit 1	Visit 1	Visit 2	Visit 2	Control group
	gr 1	gr 1	gr 2	gr 2
C-RP, mg/l	8,1 ±0,81*	10,2 ±1,54*	5,9 ±0,49	6,8 ±0,48	6,25 ±0,14
fibrinogen, g/l	3,1 ±0,14*	3,2 ±0,15*	2,4 ±0,11	2,8 ±0,14	2,85 ±0,17
MMP-2, cu	127,6 ±10,10*	134,8 ±8,84*	95,5 ±3,08	103,7 ±4,75	92,5 ±4,10
MMP-9, cu	175,8 ±19,10*	167,1 ±18,10*	110,6 ±4,86	108,5 ±4,33	103,1 ±5,55
hyaluronic acid, mg/ml	0,29 ±0,01*	0,27 ±0,01*	0,13 ±0,01	0,13 ±0,01	0,15 ±0,02

Conclusions: 1) some patients with COPD even of I and II stages in stable phase, but during inadequate treatment, has activation of systemic inflammation with increased plasma levels of C-RP, fibrinogen, MMP-2 and MMP-9, hyaluronic acid; 2) during adequate basic treatment levels of markers of systemic inflammation gradually normalized, while the "fastest reagent" is the CRP, more slowly and gradually react markers such as MMP-9 and hyaluronic acid, MMP-2.
* - p<0,05 with control group

Rating:

Share or cite this content

Citations should be made in the following way:
L. Konopkina, B. Basina (Dnipropetrovsk, Ukraine). Individual dynamic of inflammatory markers as indicators of COPD treatment effectiveness. Eur Respir J 2014; 44: Suppl. 58, 3634

Member's Comments

No comment yet.

Related content which might interest you: Biomarkers in COPD exacerbation, the role of adiponectin Source: International Congress 2014 – Predictors Year: 2014 Clinical, functional and laboratory assessment of treatment efficacy in COPD patients Source: International Congress 2014 – Predictors Year: 2014 Features of systemic inflammation in patients with stable COPD Source: International Congress 2014 – COPD: points to ponder Year: 2014 Functional Respiratory Imaging as a sensitive biomarker to assess therapeutic interventions in lung diseases Source: International Congress 2015 – Functional and imaging techniques for assessing lung, airway and respiratory muscles Year: 2015 Role of inflammatory biomarkers in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Scales of assesment in COPD. Correlation with clinical and functional parameters Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Paradoxical response to bronchodilators: Radiologic correlates and clinical implications Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 Relation of plasma osteopontin levels with the clinical course in patients with COPD Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014 U-BIOPRED asthma cohort: Inflammatory markers and corticosteroid use Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Can red blood cell morphology be an indicator for COPD exacerbations? Source: International Congress 2014 – Markers Year: 2014 Changes in inhalation therapy after combined assessment of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis Source: International Congress 2016 – Active and latent tuberculosis: biomarkers Year: 2016 Stable state MR-proadrenomedullin level in COPD patients; a validation study Source: International Congress 2014 – Comorbidities Year: 2014 The role of COPD in development of osteoporosis Source: International Congress 2014 – Markers Year: 2014 Pharmacological treatment of COPD in the on-sint cohort Source: International Congress 2014 – COPD exacerbations Year: 2014 Adrenomedullin optimizes mortality prediction in COPD Source: International Congress 2014 – COPD exacerbations Year: 2014 A multimarker approach to identify atherosclerosis in COPD Source: International Congress 2014 – Markers Year: 2014 Laboratory and clinical parameters in predicting risk of future exacerbations in both non-smoking and smoking COPD patients Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 Assessment of patients preferences regarding characteristics associated with treatment of chronic obstructive pulmonary disease Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014